Rod D Martin Net Worth

The estimated Net Worth of Rod D Martin is at least $3.29 Миллион dollars as of 13 May 2014. Rod Martin owns over 83,334 units of Galectin Therapeutics Inc stock worth over $479,012 and over the last 13 years Rod sold GALT stock worth over $2,811,200.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rod Martin GALT stock SEC Form 4 insiders trading

Rod has made over 7 trades of the Galectin Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Rod exercised 83,334 units of GALT stock worth $150,001 on 13 May 2014.

The largest trade Rod's ever made was exercising 500,000 units of Galectin Therapeutics Inc stock on 27 January 2014 worth over $1,500,000. On average, Rod trades about 108,361 units every 60 days since 2011. As of 13 May 2014 Rod still owns at least 174,822 units of Galectin Therapeutics Inc stock.

You can see the complete history of Rod Martin stock trades at the bottom of the page.

What's Rod Martin's mailing address?

Rod's mailing address filed with the SEC is 7 WELLS AVENUE, , NEWTON, MA, 02459.

Insiders trading at Galectin Therapeutics Inc

Over the last 13 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr и Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.

What does Galectin Therapeutics Inc do?

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much

Complete history of Rod Martin stock trades at Galectin Therapeutics Inc

Galectin Therapeutics Inc executives and stock owners

Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:

• Harold Shlevin,
  Director
• Jack Callicutt,
  Chief Financial Officer, Secretary
• Dr. Pol F. Boudes M.D., Ph.D.,
  Chief Medical Officer
• Dr. Pol F. Boudes,
  Chief Medical Officer
• Joel Lewis,
  Pres, CEO & Director
• Kevin Freeman,
  Independent Director
• Joel Lewis,
  President, Chief Executive Officer, Director
• Richard Uihlein,
  Independent Chairman of the Board
• Gilbert Amelio,
  Independent Director
• Gilbert Omenn,
  Independent Director
• Kary Eldred,
  Independent Director
• Eliezer Zomer,
  Executive Vice President - Manufacturing and Product Development
• Marc Rubin,
  Independent Director
• James Czirr,
  Director
• Richard Zordani,
  Independent Director
• Elissa Schwartz,
  Independent Director
• Pol Boudes,
  Chief Medical Officer
• J. Rex Horton,
  Executive Director - Regulatory Affairs and Quality Assurance
• Adam Allgood,
  Executive Director of Clinical Development
• Beth Knowles,
  Exec. Assistant & Officer Mang.
• Robert Tritt,
  Gen. Counsel
• Jack W. Callicutt CPA, CPA,
  CFO, Treasurer & Sec.
• Theodore Daniel Zucconi,
  Director
• John F Mauldin,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Steven Prelack,
  Director
• Arthur Greenberg,
  Director
• Khurram Jamil,
  Chief Medical Officer
• Benjamin Sr Carson,
  
• Stephen Shulman,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Peter G Traber,
  CEO and President
• Herman Paul Pressler,
  Director
• Thomas Mcgauley,
  Chief Financial Officer
• Rod D Martin,
  Director
• Jerald K Rome,
  Director
• Fund, L.P.Czirr James C10 X...,